Translating leukemia stem cells into the clinical setting: Harmonizing the heterogeneity.
Considerable evidence suggests that rare leukemia cells with stem cell features, including self-renewal capacity and drug resistance, are primarily responsible for both disease maintenance and relapses. Traditionally, these so-called leukemia stem cells (LSCs) have been identified in the laboratory by their ability to engraft acute myeloid leukemia (AML) into immunocompromised mice. For many years, only those rare AML cells characterized by a hematopoietic stem cell (HSC) CD34+CD38-phenotype were believed capable of generating leukemia in immunocompromised mice. However, more recently, significant heterogeneity in the phenotypes of those AML cells that can engraft immunocompromised mice has been demonstrated. AML cells that engraft immunocompromised mice have also been shown to not necessarily represent either the founder clone or those cells responsible for relapse. A recent study found that the most immature phenotype present in an AML correlated with genetically defined risk groups and outcomes, but was heterogeneous. Patients with AML cells expressing a primitive HSC phenotype (CD34+CD38-with high aldehyde dehydrogenase activity) manifested significantly lower complete remission rates, as well as poorer event-free and overall survivals. Leukemias in which the most primitive cells displayed more mature phenotypes were associated with better outcomes. The strong clinical correlations suggest that the most immature phenotype detectable within a patient's AML might serve as a biomarker for "clinically relevant" LSCs.
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
Breann
B
Yanagisawa
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
Gabriel
G
Ghiaur
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
B Douglas
BD
Smith
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA. Electronic address: rjjones@jhmi.edu.
Richard J
RJ
Jones
D000818:Animals; D015415:Biomarkers; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D018740:Genetic Heterogeneity; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000209:etiology* / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D058990:Molecular Targeted Therapy; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D010641:Phenotype; D011379:Prognosis; D059016:Tumor Microenvironment
D015415:Biomarkers
Stem Cells. 2005 Jun-Jul;23(6):752-60
15917471
Blood. 2009 Jun 11;113(24):6206-14
19050309
Leuk Res. 2014 Nov;38(11):1299-308
25262448
Leuk Lymphoma. 2015 May;56(5):1406-15
25248882
Haematologica. 2010 Jan;95(1):71-8
19648166
Br J Haematol. 2014 Jan;164(2):212-22
24152218
PLoS One. 2014 Sep 22;9(9):e107587
25244440
Int J Cancer. 2015 Aug 1;137(3):525-36
25545165
PLoS One. 2015 Sep 16;10(9):e0128998
26375984
Oncotarget. 2013 May;4(5):715-28
23651669
Blood. 1999 Sep 1;94(5):1761-72
10477702
Proc Natl Acad Sci U S A. 1967 Oct;58(4):1468-71
5237880
PLoS One. 2013 Nov 11;8(11):e78897
24244383
Blood. 2012 Apr 26;119(17):3917-24
22308295
Cell. 2009 Jul 23;138(2):271-85
19632178
Blood. 1996 Jan 1;87(1):1-13
8547630
Blood. 2004 Jul 15;104(2):550-7
15054042
Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11008-13
17576927
Blood. 2006 Feb 1;107(3):1166-73
16234360
Haematologica. 2016 May;101(5):607-16
26819054
Blood. 1995 May 15;85(10):2742-6
7742535
N Engl J Med. 2015 Nov 12;373(20):1895-8
26559569
Clin Cancer Res. 2013 Jan 15;19(2):357-66
23213054
Nature. 1994 Feb 17;367(6464):645-8
7509044
Semin Hematol. 2015 Jul;52(3):200-6
26111467
Semin Hematol. 2006 Apr;43(2):96-106
16616043
Exp Hematol. 2002 May;30(5):481-7
12031655
Exp Hematol. 2012 Feb;40(2):155-65.e1
22024109
Mol Cancer Res. 2013 Sep;11(9):1004-16
23754844
Cell. 2009 Jul 23;138(2):286-99
19632179
Oncotarget. 2015 Jun 20;6(17):14905-12
25915157
Cancer Res. 2004 Apr 15;64(8):2817-24
15087398
Haematologica. 2011 Dec;96(12):1792-8
21933861
Blood. 2009 Jun 11;113(24):6215-24
18955566
Br J Haematol. 2015 Jun 24;:null
26104974
Br J Cancer. 1969 Jun;23(2):313-28
5788039
Stem Cells. 2004;22(2):188-201
14990858
Blood. 2011 Jun 30;117(26):7112-20
21562049
Blood. 2012 Apr 12;119(15):3571-7
22262762
Leuk Lymphoma. 2016;57(6):1375-81
26422713
Am J Hematol. 2003 Jul;73(3):149-53
12827650
Cell Stem Cell. 2009 Jul 2;5(1):31-42
19570512
Leukemia. 2000 Oct;14(10):1777-84
11021753
Hum Pathol. 2013 Oct;44(10):2038-46
23701943
Cancer. 2003 Nov 15;98 (10 ):2095-104
14601078
Med Oncol. 2012 Jun;29(2):1119-26
21399995
Leuk Res. 2010 Jan;34(1):119-22
19683812
Blood. 1996 Jul 15;88(2):487-91
8695796
Cancer Chemother Pharmacol. 2003 Dec;52(6):449-52
13680159
PLoS One. 2013 Jun 27;8(6):e62785
23826077
Oncogene. 2011 Mar 3;30(9):1009-19
21076471
Cancer Res. 2015 Jun 1;75(11):2222-31
25791383
Leukemia. 2000 May;14(5):889-97
10803522
Curr Opin Genet Dev. 2012 Jun;22(3):245-50
22534183
PLoS One. 2015 Jun 05;10 (6):e0127790
26047326
Mol Cancer Ther. 2006 Dec;5(12):3113-21
17172414
Nat Med. 2016 Jul;22(7):812-21
27213817
Nat Med. 2003 Sep;9(9):1158-65
12897778
Cancer Cell. 2014 Mar 17;25(3):379-92
24613412
Br J Haematol. 2013 May;161(3):389-401
23432359
Leukemia. 2008 Feb;22(2):353-60
17972943
Nat Med. 1997 Jul;3(7):730-7
9212098
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16121-6
24043786
Blood. 2010 Nov 11;116(19):3907-22
20634376
Cytometry B Clin Cytom. 2014 Jan;86(1):3-14
24151248
J Clin Invest. 2011 Jan;121(1):384-95
21157036
Blood. 2007 Oct 1;110(7):2659-66
17609428
Ann Hematol. 2014 Nov;93(11):1819-23
24912771
Science. 2008 Dec 19;322(5909):1861-5
19095944
Blood. 2010 Mar 11;115(10):1976-84
20053758
Blood. 2005 Dec 15;106(13):4086-92
16131573
Science. 1976 Oct 1;194(4260):23-8
959840
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12 ):5009-14
21383193